Rezatapopt: A promising small-molecule "refolder" specific for TP53Y220C mutant tumors.
Kostas A Papavassiliou, Alice G Vassiliou, Athanasios G Papavassiliou
https://pubmed.ncbi.nlm.nih.gov/40543428/Actively Recruiting
Led by PMV Pharmaceuticals, Inc · Updated on 2026-10-02
300
Participants Needed
76
Research Sites
54 weeks
Total Duration
Researchers are evaluating the safety and effectiveness of PC14586 rezatapopt, an oral drug designed to reactivate the p53 protein specifically for patients with locally advanced or metastatic solid tumors that have a TP53 Y220C mutation. This Phase 12 study includes a Phase 1 portion assessing safety, tolerability, and early effects of various doses of rezatapopt alone and combined with pembrolizumab, as well as a Phase 2 portion focusing on the drugs efficacy and safety at the recommended dose in different cancer types. Participants receive daily oral doses of rezatapopt, with dose levels adjusted to find the maximum tolerated dose and recommended Phase 2 dose. Some participants receive rezatapopt alone, while others receive it combined with pembrolizumab given intravenously every three weeks. Expansion groups include patients with different tumor types such as ovarian, lung, breast, and endometrial cancers, all harboring the TP53 Y220C mutation. The study monitors participants over several months to evaluate response rates and safety. Throughout the study, participants undergo regular assessments including imaging to measure tumor response according to RECIST criteria, blood tests to study drug levels and safety, and quality of life questionnaires. Safety is closely monitored by tracking adverse events. The total study duration varies but includes extended follow-up of up to 34 months in Phase 2. The trial is non-randomized and open-label, allowing researchers to gather detailed information on the drugs effects in this patient population.
CONDITIONS
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
P
PMV Pharma Clinical Study Information Center
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
PMV Pharmaceuticals, Inc
Lead Sponsor
Merck Sharp & Dohme LLC
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Investigational: rezatapopt (± pembrolizumab) | Context: current standard options |
|---|---|---|
| What it is | An investigational oral small molecule that selectively reactivates mutant p53 bearing the TP53 Y220C alteration, given alone or with pembrolizumab in dose escalation and expansion cohorts. | There is no approved therapy targeting TP53 Y220C mutations; patients are typically managed per tumor type with standard chemotherapy, checkpoint inhibitors, or other established treatments based on histology. |
| Role in trial | Investigational treatment being tested for safety, dosing, and preliminary efficacy in patients with TP53 Y220C–mutant tumors. | Serves as a reference for therapeutic options outside the investigational setting, rather than being studied in this trial. |
| Primary use | To reactivate mutant p53 Y220C and assess safety, optimal dose, and preliminary anti‑tumor activity. | To treat advanced solid tumors using current histology‑based standard options, informed by tumor type and prior therapies. |
| How it is given or performed | Oral administration of rezatapopt once daily in continuous 21‑day cycles, alone or following a lead‑in and combined with intravenous pembrolizumab in selected cohorts. | Clinic‑based administration depending on the chosen therapy: e.g., intravenous chemotherapy or immunotherapy, or oral agents as per standard protocols. |
| Evidence status | Early clinical data show a 20% overall response across tumor types and 30% in KRAS wild‑type tumors at recommended dose, with manageable safety profile. | Efficacy depends on tumor type and prior treatments; no data specific to TP53 Y220C mutation context. |
| Important risks | Common treatment‑related adverse events include nausea, vomiting, elevated creatinine, fatigue, and anemia; grade 3+ anemia occurred in 16%, with 3% discontinuation due to adverse events. | Safety and risks vary by treatment modality (chemotherapy, immunotherapy); not specifically defined for TP53 mutant context. |
| Important limitations | Response data are preliminary from early phase cohorts without randomized comparison; long‑term benefit and applicability across tumor types remain under investigation. | Standard treatments are not mutation‑specific and may be less effective in TP53 mutant cancers; outcomes vary widely by cancer type and prior lines of therapy. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 34 months
Participants receive daily oral doses of rezatapopt alone or combined with pembrolizumab given intravenously every three weeks. Dose levels are adjusted to find the best tolerated dose and to evaluate safety and early response.
Regular visits during treatment
Duration - Up to 34 months
Participants are monitored with imaging scans, blood tests, and questionnaires to assess tumor response, drug levels, safety, and quality of life throughout and after treatment.
Visits at regular intervals for assessments
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
9
Have more questions? Get in touch with our team for quick support
Kostas A Papavassiliou, Alice G Vassiliou, Athanasios G Papavassiliou
https://pubmed.ncbi.nlm.nih.gov/40543428/Alison M Schram, Marc Fellous, Kim LeDuke...
https://pubmed.ncbi.nlm.nih.gov/40932470/Ecaterina E Dumbrava, Geoffrey I Shapiro, Aparna R Parikh...
https://pubmed.ncbi.nlm.nih.gov/41740031/PMV Pharmaceuticals, Inc
Lead Sponsor
Merck Sharp & Dohme LLC
Collaborating Sponsor